Breast trials now recruiting
TROG 17.05 AZTEC - this trial aims to compare the efficacy of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with Atezolizumab in patients with advanced Triple Negative Breast Cancer.
Primary sponsor: Peter MacCallum Cancer Centre
Contract Research Organisation: TROG
TROG 16.04 / ANZ1601 / BIG1602 (EXPERT) - The aim of this study is to tailor radiotherapy utilisation after breast conserving surgery for people with low-risk luminal A early breast cancer, to the individual’s recurrence risks by identifying patients who are unlikely to benefit from radiotherapy.
Primary sponsor: Breast Cancer Trials
Collaborating groups: Big International Group (BIG); International Breast Cancer Study Group (IBCSG); TROG
TROG 16.03 (CORE) - this study aims to show that the addition of SBRT (stereotactic body radiotherapy) to standard of care improves progression free survival for patients with extra-cranial oligiometastatic disease that has spread from their lung, breast and/or prostate cancer.
Primary sponsor: Institute of Cancer Research (ICR)
Collaborating groups: TROG
TROG 16.02 (LOCAL HER-O) - This study aims to show that brain metastasis, from HER2 positive breast cancer, are able to be controlled by Stereotactic Radiosurgery and/or Neurosurgery without the need for WBRT.
Primary Sponsor: TROG
TROG 12.02 (PET LABRADOR) - this study is investigating whether women with locally advanced breast cancer can have breast conservation surgery (BCS) instead of mastectomy, with a low chance of cancer coming back in the breast. The study also investigates if breast Magnetic Resonance Imaging (MRI) and PET-CT are better ways of seeing how breast cancer responds to chemotherapy or hormone therapy compared to mammogram, ultrasound and examination by doctors.
Primary sponsor: TROG